Syntara (SNT) Stock Overview
A clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SNT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Syntara Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.023 |
| 52 Week High | AU$0.04 |
| 52 Week Low | AU$0.019 |
| Beta | 0.18 |
| 1 Month Change | -11.54% |
| 3 Month Change | -4.17% |
| 1 Year Change | -11.54% |
| 3 Year Change | -32.35% |
| 5 Year Change | -81.96% |
| Change since IPO | -94.89% |
Recent News & Updates
Regulatory Clarity On Myelofibrosis Trials Will Support Long Term Hematology And Neurology Upside
Catalysts About Syntara Syntara is a biotech company focused on developing therapies in hematology, neurology and dermatology, including amsulostat and SNT-4728. What are the underlying business or industry changes driving this perspective?
Phase IIb Myelofibrosis Catalyst Will Drive Long-Term Upside Potential
Catalysts About Syntara Syntara is a clinical stage biotech company developing amsulostat and other drug candidates targeting myelofibrosis, myelodysplastic syndromes, Parkinson's related conditions and pathological scarring. What are the underlying business or industry changes driving this perspective?Recent updates
Regulatory Clarity On Myelofibrosis Trials Will Support Long Term Hematology And Neurology Upside
Catalysts About Syntara Syntara is a biotech company focused on developing therapies in hematology, neurology and dermatology, including amsulostat and SNT-4728. What are the underlying business or industry changes driving this perspective?Phase IIb Myelofibrosis Catalyst Will Drive Long-Term Upside Potential
Catalysts About Syntara Syntara is a clinical stage biotech company developing amsulostat and other drug candidates targeting myelofibrosis, myelodysplastic syndromes, Parkinson's related conditions and pathological scarring. What are the underlying business or industry changes driving this perspective?Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Syntara ( ASX:SNT...Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified
Syntara Limited ( ASX:SNT ) shares have continued their recent momentum with a 36% gain in the last month alone. Not...Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Syntara Limited ( ASX:SNT ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement
You may think that with a price-to-sales (or "P/S") ratio of 1.2x Syntara Limited ( ASX:SNT ) is definitely a stock...We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
In the past three years, the share price of Pharmaxis Ltd ( ASX:PXS ) has struggled to grow and now shareholders are...Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Gary Phillips became the CEO of Pharmaxis Ltd ( ASX:PXS ) in 2013, and we think it's a good time to look at the...We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...Shareholder Returns
| SNT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -8.0% | 1.8% | 0.003% |
| 1Y | -11.5% | -12.3% | -2.0% |
Return vs Industry: SNT matched the Australian Pharmaceuticals industry which returned -12.3% over the past year.
Return vs Market: SNT underperformed the Australian Market which returned -2% over the past year.
Price Volatility
| SNT volatility | |
|---|---|
| SNT Average Weekly Movement | 14.1% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 3.9% |
Stable Share Price: SNT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: SNT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Gary Phillips | syntaratx.com.au |
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation.
Syntara Limited Fundamentals Summary
| SNT fundamental statistics | |
|---|---|
| Market cap | AU$45.12m |
| Earnings (TTM) | -AU$9.61m |
| Revenue (TTM) | AU$6.93m |
Is SNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNT income statement (TTM) | |
|---|---|
| Revenue | AU$6.93m |
| Cost of Revenue | AU$7.38m |
| Gross Profit | -AU$450.00k |
| Other Expenses | AU$9.16m |
| Earnings | -AU$9.61m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0049 |
| Gross Margin | -6.49% |
| Net Profit Margin | -138.71% |
| Debt/Equity Ratio | 0% |
How did SNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 05:59 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syntara Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |
| Madeleine Williams | Canaccord Genuity |